AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22341824 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care.
Number of subjects: 15261
Study 22341824 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention specifically for young adult women and FSWs.
Number of subjects: 15261
Study 21098443 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial infarction (MI)
Number of subjects: 190915
Study 18670365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of low-dose simvastatin 10 mg with ezetimibe 10 mg
Number of subjects: 19
Study 18670365 — intervention group
Group type: COMPARATOR
Intervention: High-dose simvastatin 80 mg
Number of subjects: 19
Study 16002796 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid/d for 3 weeks
Number of subjects: 41
Study 16002796 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 41
Study 12450886 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fatty acids diet (total fat, 36% of energy; SFAs, 18% of energy; MUFAs, 10% of energy)
Number of subjects: 32
Study 12450886 — intervention group
Group type: COMPARATOR
Intervention: Monounsaturated fatty acids diet (total fat, 35% of energy; SFAs, 9% of energy; MUFAs, 19% of energy)
Number of subjects: 32
Study 12450886 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids supplementation (3.6 g n-3 fatty acids/d; 2.4 g eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3))
Number of subjects: 32
Study 12450886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10605601 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of salicylic acid in ethanol solution
Number of subjects: 2
Study 10605601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 2 g acetylsalicylic acid
Number of subjects: 2
Study 8557785 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) dosage of 22.8 +/- 10.3 mg/kg/day
Number of subjects: 32
Study 1954079 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg
Number of subjects: 15
Study 1954079 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg plus Triamterene 50 mg
Number of subjects: 15
Study 1954079 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline alone
Number of subjects: 15
Study 1954079 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg plus Terbutaline
Number of subjects: 15
Study 1954079 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg plus Triamterene 50 mg plus Terbutaline
Number of subjects: 15
Study 6751166 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg daily for 24 months
Number of subjects: 22
Study 6751166 — intervention group
Group type: COMPARATOR
Intervention: placebo-control period
Number of subjects: 22
Study 31996192 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + Sn (screen-time and unhealthy snacking)
Number of subjects: 75
Study 31996192 — intervention group
Group type: EXPERIMENTAL
Intervention: ST (screen-time only)
Number of subjects: 75
Study 31996192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn (unhealthy snacking only)
Number of subjects: 75
Study 31996192 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents in ST + Sn and ST groups
Number of subjects: 75
Study 31996192 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 30942150 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (1.5 ml L-1) plus gibberellin
Number of subjects: 0
Study 30942150 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (4.5 ml L-1) under optimum water level
Number of subjects: 0
Study 30942150 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (4.5 ml L-1) plus gibberellin under severe water stress
Number of subjects: 0
Study 28402237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold
Number of subjects: 1845
Study 28402237 — intervention group
Group type: COMPARATOR
Intervention: Metallic stent
Number of subjects: 1845
Study 25886152 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive Oil
Number of subjects: 831
Study 25886152 — intervention group
Group type: COMPARATOR
Intervention: HOFA
Number of subjects: 831
Study 23962028 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) + Exemestane (EXE)
Number of subjects: 724
Study 23962028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Exemestane (EXE)
Number of subjects: 724
Study 21200342 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 25
Study 21200342 — intervention group
Group type: COMPARATOR
Intervention: Placebo-IMT
Number of subjects: 25
Study 19519260 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 151
Study 19519260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 17244316 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrysalin (TP508) applied topically, twice weekly
Number of subjects: 60
Study 17244316 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) applied topically, twice weekly
Number of subjects: 60
Study 14703471 — intervention group
Group type: EXPERIMENTAL
Intervention: IgY solution
Number of subjects: 44
Study 14703471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10737482 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 1229
Study 10737482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1229
Study 8912445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostakath (first-generation stent)
Number of subjects: 117
Study 8912445 — intervention group
Group type: EXPERIMENTAL
Intervention: ProstaCoil (second-generation stent)
Number of subjects: 117
Study 8912445 — intervention group
Group type: COMPARATOR
Intervention: Both stents
Number of subjects: 117
Study 1424192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy for 3 months
Number of subjects: 80
Study 1424192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2869618 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 2869618 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy (coronary artery bypass surgery)
Number of subjects: 0
Study 30670251 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 39
Study 30670251 — intervention group
Group type: COMPARATOR
Intervention: HT Sham
Number of subjects: 39
Study 30670251 — intervention group
Group type: COMPARATOR
Intervention: Control with aide (CP)
Number of subjects: 39
Study 30670251 — intervention group
Group type: COMPARATOR
Intervention: Control without aide (CNP)
Number of subjects: 39
Study 27827397 — intervention group
Group type: EXPERIMENTAL
Intervention: high-MC-SFA supplementation
Number of subjects: 52
Study 27827397 — intervention group
Group type: COMPARATOR
Intervention: low-MC-SFA butter
Number of subjects: 52
Study 27827397 — intervention group
Group type: EXPERIMENTAL
Intervention: high-MC-SFA butter
Number of subjects: 52
Study 25776110 — intervention group
Group type: EXPERIMENTAL
Intervention: Moms and Teens for Safe Dates program (six mailed booklets of dating abuse prevention information and interactive activities)
Number of subjects: 409
Study 25776110 — intervention group
Group type: EXPERIMENTAL
Intervention: Moms and Teens for Safe Dates program
Number of subjects: 409
Study 23312562 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavior therapy (8-week program)
Number of subjects: 55
Study 23312562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment Clinician Administered PTSD Scale severity
Number of subjects: 55
Study 21035202 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults (mean age: 20)
Number of subjects: 53
Study 21035202 — intervention group
Group type: COMPARATOR
Intervention: Older adults (mean age: 77)
Number of subjects: 53
Study 19948642 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for diabetes (negative test result)
Number of subjects: 5334
Study 19948642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 5334
Study 17276100 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings for one week
Number of subjects: 300
Study 17276100 — intervention group
Group type: COMPARATOR
Intervention: Graduated elastic compression stockings for three weeks
Number of subjects: 300
Study 15542294 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 181
Study 15542294 — intervention group
Group type: COMPARATOR
Intervention: Coronary balloon angioplasty
Number of subjects: 181
Study 11832846 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and information programme for lay caregivers
Number of subjects: 0
Study 9793288 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 ppm fluoride dentifrice
Number of subjects: 0
Study 9793288 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride dentifrice
Number of subjects: 0
Study 9793288 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 1500 ppm F dentifrice and non-fluoride dentifrice
Number of subjects: 0
Study 7702230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin with alcohol (40 mg/d + 20 g ethanol diluted to 20% with orange juice)
Number of subjects: 31
Study 7702230 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin alone (40 mg/d + orange juice)
Number of subjects: 31
Study 2695556 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injections of clindamycin
Number of subjects: 29
Study 2695556 — intervention group
Group type: COMPARATOR
Intervention: Oral pyrimethamine and sulfadiazine (P + S)
Number of subjects: 29
Study 319642 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 30
Study 319642 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30
Study 319642 — intervention group
Group type: EXPERIMENTAL
Intervention: P/D (Propranolol and Digoxin combination)
Number of subjects: 30
Study 319642 — intervention group
Group type: EXPERIMENTAL
Intervention: P/D
Number of subjects: 30
Study 31145387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical training group (back-half-squat)
Number of subjects: 24
Study 31145387 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal training group (barbell hip-thrust)
Number of subjects: 24
Study 31145387 — intervention group
Group type: COMPARATOR
Intervention: Control group (general strength training)
Number of subjects: 24
Study 30232744 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus acidophilus La5, Bifidobacterium BB12, and Lactobacillus casei DN001 (108 CFU/g each)
Number of subjects: 60
Study 30232744 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 60
Study 30232744 — intervention group
Group type: COMPARATOR
Intervention: Regular yogurt
Number of subjects: 60
Study 28281218 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0
Study 28281218 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine U100
Number of subjects: 0
Study 25496176 — intervention group
Group type: COMPARATOR
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV), administered to 52 children, monitored for 3 years.
Number of subjects: 109
Study 25496176 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated children), monitored for 3 years.
Number of subjects: 109
Study 25496176 — intervention group
Group type: COMPARATOR
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV)
Number of subjects: 109
Study 23175691 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1 g in the morning and 500 mg in the evening for 6 months
Number of subjects: 151
Study 23175691 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 151
Study 23175691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 22090227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular hypothermia (group A, n = 20)
Number of subjects: 41
Study 22090227 — intervention group
Group type: COMPARATOR
Intervention: Traditional cooling (group B, n = 21)
Number of subjects: 41
Study 19917733 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrical stimulation combined with stretching exercises and foot orthoses
Number of subjects: 26
Study 19917733 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises and foot orthoses (Control)
Number of subjects: 26
Study 17086374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernioplasty for primary inguinal hernia
Number of subjects: 362
Study 17086374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernioplasty for recurrent inguinal hernia
Number of subjects: 362
Study 12559241 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily discrimination training task using an oddball paradigm with cutaneous electrical stimuli for 3 weeks
Number of subjects: 40
Study 12559241 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 40
Study 10594492 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC-HFA (CFC-free inhaler with hydrofluoroalkane)
Number of subjects: 10
Study 10594492 — intervention group
Group type: COMPARATOR
Intervention: BEC-CFC (CFC-based inhaler)
Number of subjects: 10
Study 8697722 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous lithium clearance (CLi)
Number of subjects: 12
Study 8697722 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous lithium clearance (CLi) with 450 mg lithium
Number of subjects: 12
Study 8697722 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous lithium clearance (CLi) with 600 mg lithium
Number of subjects: 12
Study 8697722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional excretion of lithium (FELi) with endogenous lithium
Number of subjects: 12
Study 8697722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional excretion of lithium (FELi) with 450 mg lithium
Number of subjects: 12
Study 8697722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional excretion of lithium (FELi) with 600 mg lithium
Number of subjects: 12
Study 12797080 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal chorionic villus sampling
Number of subjects: 3347
Study 12797080 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 3347
Study 12797080 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical chorionic villus sampling
Number of subjects: 3347
Study 6982566 — intervention group
Group type: EXPERIMENTAL
Intervention: lonazolac-Ca (200 mg t.i.d.)
Number of subjects: 6
Study 6982566 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac-Na (50 mg t.i.d.)
Number of subjects: 6
Study 6982566 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin (50 mg t.i.d.)
Number of subjects: 6
Study 6982566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during wash-out period)
Number of subjects: 6
Study 3902682 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream
Number of subjects: 227
Study 3902682 — intervention group
Group type: COMPARATOR
Intervention: 0.05% fluocinonide cream
Number of subjects: 227
Study 29735021 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg/day (PRED30; n=12)
Number of subjects: 32
Study 29735021 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg/day (PRED7.5; n=12)
Number of subjects: 32
Study 29735021 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 32
Study 27723699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ademetionin 400 mg 2 times a day for 7 days
Number of subjects: 100
Study 27723699 — intervention group
Group type: COMPARATOR
Intervention: Remaxol 400 ml once a day for 7 days
Number of subjects: 100
Study 24575806 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened extensive casein hydrolysate (T‐eCH)
Number of subjects: 72
Study 24575806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthickened extensive casein hydrolysate (NT‐eCH)
Number of subjects: 72
Study 24575806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both T‐eCH and NT‐eCH
Number of subjects: 72
Study 22622786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin prototype colonoscope
Number of subjects: 187
Study 22622786 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscope
Number of subjects: 187
Study 20619382 — intervention group
Group type: COMPARATOR
Intervention: HCV E1E2 vaccine adjuvanted with MF59, administered at 3 different dosages on day 0 and weeks 4, 24, and 48.
Number of subjects: 0
Study 20619382 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV E1E2 vaccine adjuvanted with MF59.
Number of subjects: 0
Study 18584523 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 34
Study 18584523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15798007 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intervention
Number of subjects: 154
Study 15798007 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month intervention
Number of subjects: 154
Study 12708964 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 2x900 mg doses
Number of subjects: 18
Study 12708964 — intervention group
Group type: COMPARATOR
Intervention: Methionine loading without NAC (Met group)
Number of subjects: 18
Study 10574809 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin treatment
Number of subjects: 121
Study 10574809 — intervention group
Group type: COMPARATOR
Intervention: Control group (deferred treatment)
Number of subjects: 121
Study 8923816 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses produced certain action effects: tones on the left versus the right or tones of low versus high pitch.
Number of subjects: 0
Study 1994609 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy in persons with positive Hemoccult‐II tests
Number of subjects: 0
Study 1994609 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected adenomas
Number of subjects: 0
Study 1994609 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms related to adenomas
Number of subjects: 0
Study 1994609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperplastic polyps
Number of subjects: 0
Study 1994609 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic polypectomy
Number of subjects: 0
Study 1994609 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal
Number of subjects: 0
Study 6978687 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte solution (Group A)
Number of subjects: 40
Study 6978687 — intervention group
Group type: COMPARATOR
Intervention: Blood from the pump‐oxygenator (Group B)
Number of subjects: 40
Study 6978687 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of Group A and Group B
Number of subjects: 40
Study 31256674 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPE liner
Number of subjects: 89
Study 31256674 — intervention group
Group type: COMPARATOR
Intervention: ModXLPE liner
Number of subjects: 89
Study 31256674 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPE and ModXLPE
Number of subjects: 89
Study 31256674 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with radiolucency
Number of subjects: 89
Study 31256674 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC shells
Number of subjects: 89
Study 29893003 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin 50 mg
Number of subjects: 124
Study 29893003 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin
Number of subjects: 124
Study 29893003 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 124
Study 26643400 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational programme (PEP)
Number of subjects: 86
Study 26643400 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 86
Study 24100783 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated diagnostic protocol (Thrombolysis in Myocardial Infarction score, 0; electrocardiography; and 0- and 2-hour troponin tests)
Number of subjects: 542
Study 24100783 — intervention group
Group type: COMPARATOR
Intervention: Standard-care pathway (troponin test on arrival, prolonged observation, and a second troponin test 6-12 hours after onset of pain)
Number of subjects: 542
Study 24100783 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 542
Study 23023840 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management (MTM) intervention
Number of subjects: 637
Study 23023840 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MTM
Number of subjects: 637
Study 23023840 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 637
Study 19943165 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA
Number of subjects: 186
Study 19943165 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day ASA and 75 mg/day clopidogrel
Number of subjects: 186
Study 19943165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-platelet medication)
Number of subjects: 186
Study 18440727 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 240
Study 18440727 — intervention group
Group type: COMPARATOR
Intervention: cRT
Number of subjects: 240
Study 16003270 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain rate (SR) imaging
Number of subjects: 77
Study 16003270 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal values)
Number of subjects: 77
Study 11812696 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective spinal anesthesia (SSA) with lidocaine 10 mg + sufentanil 10 microg
Number of subjects: 20
Study 11812696 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia (DES) and N(2)O
Number of subjects: 20
Study 11812696 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective spinal anesthesia (SSA)
Number of subjects: 20
Study 11812696 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia (DES)
Number of subjects: 20
Study 10098808 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and a guide book
Number of subjects: 50
Study 10098808 — intervention group
Group type: COMPARATOR
Intervention: Guide book only
Number of subjects: 50